Skip to Main Content

Intercept Pharmaceuticals said Thursday that an extensive re-analysis of a large clinical trial involving its experimental treatment for the fatty liver disease known as NASH once again achieved its primary efficacy goal.

The company intends to use the new data to resubmit a marketing application in the U.S., although its approvability is likely to remain a hotly debated question.


The Food and Drug Administration rejected Intercept’s original marketing application for the NASH drug called obeticholic acid, or OCA, in June 2020. Regulators were concerned that the efficacy analyses read from liver biopsy slides by a single physician were too unreliable, particularly given the drug’s reported side effects.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.